Biopsy Device Market Size, Share, Growth, and Industry Analysis, Types (Guidance System, Needles, Guns, Reagents and Kits, Others), Applications (Hospital, Specialised Oncology Centres, Diagnostic Centres, Research Institutes), and Regional Insights and Forecast to 2035

Biopsy Device Market Size

The Global Biopsy Device Market size was USD 2.12 Billion in 2025 and is projected to touch USD 2.21 Billion in 2026, rise to USD 2.30 Billion in 2027, and reach USD 3.18 Billion by 2035, exhibiting a CAGR of 4.11% during the forecast period [2026–2035]. Nearly 63% of diagnostic confirmations in oncology rely on biopsy results. Around 49% of healthcare providers prioritize minimally invasive biopsy solutions, while 41% emphasize procedural efficiency improvements.

The US Biopsy Device Market shows consistent growth supported by strong screening programs and outpatient diagnostics. Around 68% of biopsy procedures in the US are performed using image guidance. Nearly 54% of hospitals rely on automated biopsy guns, while 39% of procedures are conducted in diagnostic centers, reflecting decentralized care models.

Key Findings

• Market Size: Valued at $2.12Bn in 2025, projected to touch $2.21Bn in 2026 and $3.18Bn by 2035 at a CAGR of 4.11%.
• Growth Drivers: Early diagnosis reliance 69%, image-guided procedures 67%, outpatient adoption 36%.
• Trends: Disposable devices 48%, automation usage 42%, precision targeting 51%.
• Key Players: Becton, Dickinson and Company, Hologic, Boston Scientific, Cook Medical, Argon Medical & more.
• Regional Insights: North America 38%, Europe 27%, Asia-Pacific 25%, Middle East & Africa 10%.
• Challenges: Skilled operator gap 45%, patient anxiety 38%, equipment access 29%.
• Industry Impact: Diagnostic accuracy improvement 52%, recovery time reduction 44%, workflow efficiency 39%.
• Recent Developments: Automation adoption 24%, disposable kits 28%, imaging integration 33%.

One unique aspect of the Biopsy Device Market is the growing use of biopsy samples for molecular and genetic testing. Nearly 31% of biopsy procedures now support precision medicine workflows, increasing the diagnostic value of each tissue sample without increasing procedure frequency.

Biopsy Device Market Trends

The Biopsy Device Market is steadily evolving as early diagnosis and minimally invasive procedures become routine across healthcare systems. Around 67% of clinicians now prefer image-guided biopsy procedures due to improved sampling accuracy and lower complication rates. Nearly 59% of hospitals report a shift from open surgical biopsies toward needle-based techniques, reducing patient recovery time. Automation is another visible trend, with about 42% of newly adopted biopsy devices featuring semi-automated or fully automated firing mechanisms. Disposable biopsy components are gaining traction, accounting for nearly 48% of total usage, largely driven by infection control priorities. Precision continues to improve, as close to 51% of healthcare providers highlight better tissue targeting with modern guidance systems. In oncology-focused settings, approximately 63% of diagnostic workflows now include biopsy as a first-line confirmatory step. These trends reflect a market focused on accuracy, patient safety, and procedural efficiency rather than volume expansion alone.

Biopsy Device Market Dynamics

OPPORTUNITY

"Expansion of minimally invasive diagnostics"

Minimally invasive diagnostics create strong opportunities for the Biopsy Device Market. Nearly 61% of healthcare providers prefer biopsy techniques that reduce patient trauma and hospital stay. About 47% of diagnostic centers are upgrading to advanced biopsy guns and guidance systems to improve workflow efficiency. In addition, approximately 35% of institutions are expanding outpatient biopsy services, opening new demand for portable and easy-to-use biopsy devices.

DRIVERS

"Rising focus on early cancer detection"

Early cancer detection is a key driver for the Biopsy Device Market. Around 69% of oncologists rely on biopsy results to confirm malignancy before treatment planning. Nearly 54% of screening programs integrate biopsy as a follow-up diagnostic step. Growing awareness among patients has also contributed, with about 41% more individuals opting for confirmatory diagnostic procedures.

RESTRAINTS

"Procedure-related discomfort and risk"

Despite advancements, biopsy procedures still face restraints linked to patient discomfort and procedural risk. Nearly 38% of patients express anxiety related to invasive diagnostic tests. About 33% of healthcare providers report concerns around bleeding and infection risks, particularly in complex biopsies. These factors can limit procedure acceptance in certain patient groups.

CHALLENGE

"Access to skilled professionals and equipment"

A major challenge in the Biopsy Device Market is access to trained professionals. Around 45% of smaller diagnostic centers report limited availability of skilled operators for image-guided biopsies. Additionally, nearly 29% face challenges in maintaining advanced guidance systems, affecting consistent adoption across regions.

Segmentation Analysis

According to industry assessment, the Global Biopsy Device Market size was USD 2.12 Billion in 2025 and is projected to touch USD 2.21 Billion in 2026, rise further to USD 2.30 Billion in 2027, and reach USD 3.18 Billion by 2035, exhibiting a CAGR of 4.11% during the forecast period [2026–2035]. Segmentation analysis shows how device type and end-use settings influence purchasing patterns and clinical adoption.

By Type

Guidance System

Guidance systems play a critical role in improving biopsy accuracy. Nearly 56% of complex biopsies rely on imaging guidance for precise tissue targeting. About 49% of clinicians report reduced repeat procedures when guidance systems are used effectively.

Guidance System held a significant share in the Biopsy Device Market, accounting for USD 0.71 Billion in 2026, representing around 32% of the total market. This segment is expected to grow at a CAGR of 4.11% from 2026 to 2035, driven by demand for accuracy and reliability.

Needles

Biopsy needles remain essential due to their simplicity and cost-effectiveness. Approximately 62% of routine biopsies use disposable needles. Around 44% of providers value improved needle designs that minimize tissue damage.

Needles accounted for USD 0.66 Billion in 2026, representing nearly 30% share. This segment is projected to grow at a CAGR of 4.11% from 2026 to 2035.

Guns

Biopsy guns are widely adopted for automated tissue sampling. Nearly 48% of hospitals prefer spring-loaded or vacuum-assisted guns for consistent sampling depth. Efficiency remains the key advantage.

Guns generated USD 0.46 Billion in 2026, accounting for about 21% of the market. This segment is expected to grow at a CAGR of 4.11% from 2026 to 2035.

Reagents and Kits

Reagents and kits support sample preservation and preparation. Around 39% of diagnostic workflows rely on standardized biopsy kits to ensure consistency.

Reagents and Kits contributed USD 0.26 Billion in 2026, representing nearly 12% share. This segment is projected to grow at a CAGR of 4.11% from 2026 to 2035.

Others

Other biopsy-related tools include accessories and consumables. About 23% of providers use customized accessories based on procedure type.

Other types accounted for USD 0.12 Billion in 2026, representing around 5% share. This segment is expected to grow at a CAGR of 4.11% from 2026 to 2035.

By Application

Hospital

Hospitals dominate biopsy procedures due to advanced infrastructure and specialist availability. Nearly 58% of biopsies are performed in hospital settings.

Hospitals accounted for USD 0.93 Billion in 2026, representing around 42% of the market. This segment is expected to grow at a CAGR of 4.11% from 2026 to 2035.

Specialised Oncology Centres

Specialised oncology centres focus on precision diagnostics. Around 46% of cancer-related biopsies are conducted in these centers.

Specialised Oncology Centres generated USD 0.60 Billion in 2026, accounting for nearly 27% share. This segment is projected to grow at a CAGR of 4.11% from 2026 to 2035.

Diagnostic Centres

Diagnostic centres offer outpatient biopsy services. Nearly 39% of patients prefer diagnostic centers for convenience and faster turnaround.

Diagnostic Centres accounted for USD 0.44 Billion in 2026, representing about 20% share. This segment is expected to grow at a CAGR of 4.11% from 2026 to 2035.

Research Institutes

Research institutes use biopsy devices for clinical studies and trials. Around 18% of advanced biopsy tools are used in research environments.

Research Institutes contributed USD 0.24 Billion in 2026, accounting for nearly 11% share. This segment is projected to grow at a CAGR of 4.11% from 2026 to 2035.

Biopsy Device Market Regional Outlook

According to industry assessment, the Global Biopsy Device Market size was USD 2.12 Billion in 2025 and is projected to touch USD 2.21 Billion in 2026, rise further to USD 2.30 Billion in 2027, and reach USD 3.18 Billion by 2035, exhibiting a CAGR of 4.11% during the forecast period [2026–2035]. Regional performance varies based on healthcare infrastructure maturity, cancer screening penetration, availability of trained specialists, and adoption of image-guided diagnostic procedures. Developed regions focus on precision and minimally invasive workflows, while emerging regions concentrate on access expansion and diagnostic capacity building.

North America

North America remains the largest regional contributor to the Biopsy Device Market, driven by advanced diagnostic infrastructure and high cancer screening rates. Around 71% of biopsy procedures in the region are image-guided, improving diagnostic accuracy. Nearly 62% of hospitals use automated biopsy guns to standardize tissue sampling. Outpatient diagnostic centers account for approximately 36% of procedures, reflecting a shift toward same-day diagnostics and reduced hospital stays.

North America held approximately 38% of the global Biopsy Device Market in 2026, supported by early technology adoption and strong clinical guidelines for biopsy-based diagnosis.

Europe

Europe shows steady demand for biopsy devices, supported by structured cancer screening programs and public healthcare coverage. Nearly 64% of oncology diagnoses in the region rely on biopsy confirmation. About 48% of facilities emphasize reusable core biopsy systems to manage procedural costs. Diagnostic centers play a growing role, contributing close to 29% of biopsy volumes across major European markets.

Europe accounted for around 27% of the global market share in 2026, reflecting consistent utilization across hospital and specialized oncology settings.

Asia-Pacific

Asia-Pacific is the fastest-growing region in terms of biopsy procedure volume due to expanding healthcare access and rising cancer awareness. Around 58% of newly established diagnostic centers in urban areas now offer biopsy services. Approximately 44% of hospitals are upgrading to modern biopsy guidance systems to improve early detection outcomes. Growing medical tourism also supports procedure growth.

Asia-Pacific represented nearly 25% of the global Biopsy Device Market in 2026, driven by rising patient volumes and healthcare infrastructure investment.

Middle East & Africa

Middle East & Africa shows gradual growth in biopsy device adoption as diagnostic capabilities improve. Around 41% of tertiary hospitals in the region perform routine biopsy procedures. Public healthcare initiatives account for nearly 33% of diagnostic expansions. Limited access outside urban centers remains a constraint, but steady improvement is visible.

Middle East & Africa held close to 10% of the global market share in 2026, supported by expanding hospital networks and oncology services.

List of Key Biopsy Device Market Companies Profiled

Investment Analysis and Opportunities in Biopsy Device Market

Investment activity in the Biopsy Device Market is centered on improving diagnostic accuracy, procedural safety, and workflow efficiency. Nearly 46% of investments focus on image-guided biopsy systems that enhance tissue targeting. Around 38% of funding is directed toward automation to reduce operator variability. Disposable biopsy components attract close to 34% of investment as infection control remains a priority. Emerging markets account for approximately 29% of new capital deployment, aimed at expanding diagnostic access. Research-driven investments represent about 26%, supporting development of precision biopsy tools for oncology and molecular diagnostics. These trends highlight opportunities for manufacturers offering integrated, easy-to-use, and scalable biopsy solutions.

New Products Development

New product development in the Biopsy Device Market emphasizes precision, patient comfort, and clinical efficiency. Nearly 42% of new devices feature enhanced needle designs to improve sample quality. About 37% integrate compatibility with ultrasound or imaging platforms. Compact and portable biopsy systems represent around 31% of recent launches, supporting outpatient and diagnostic center use. Single-use biopsy kits account for nearly 35% of product introductions, aligning with infection prevention standards. These developments reflect a shift toward safer, faster, and more standardized biopsy procedures.

Recent Developments

• Advanced core biopsy systems: In 2025, manufacturers launched systems improving tissue sample adequacy by nearly 21%.
• Image-guided integration: New devices improved targeting accuracy for approximately 33% of image-assisted procedures.
• Disposable biopsy kits: Adoption increased by nearly 28% to support infection control protocols.
• Automation enhancements: Automated biopsy guns reduced procedure time by around 24%.
• Portable biopsy solutions: Compact systems expanded outpatient procedure capability by nearly 19%.

Report Coverage

This report provides comprehensive coverage of the Biopsy Device Market, including market size trends, regional outlook, segmentation by type and application, competitive landscape, and innovation activity. Around 66% of the analysis focuses on oncology-driven demand due to the critical role of biopsy in cancer diagnosis. Regional insights account for 100% of global market distribution across North America, Europe, Asia-Pacific, and Middle East & Africa. Technology assessment highlights that nearly 52% of biopsy procedures now rely on image-guided systems. Competitive profiling covers major manufacturers representing over 70% of market participation. The report also evaluates investment trends, product development activity, and clinical adoption patterns shaping long-term market growth.

Biopsy Device Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2.12 Billion in 2026
Market Size Value By	USD 3.18 Billion by 2035
Growth Rate	CAGR of 4.11% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Hospital Specialised Oncology Centres Diagnostic Centres Research Institutes By Application : Guidance System Needles Guns Reagents and Kits Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Download FREE Sample

Full Name*

Business Email*

Phone No.

Security Code

Submit

Frequently Asked Questions

• What value is the Biopsy Device Market expected to touch by 2035?

  The global Biopsy Device Market is expected to reach USD 3.18 Billion by 2035.

• What CAGR is the Biopsy Device Market expected to exhibit by 2035?

  The Biopsy Device Market is expected to exhibit a CAGR of 4.11% by 2035.

• Who are the top players in the Biopsy Device Market?

  Becton, Dickinson and Company, Argon Medical, B. Braun Melsungen AG, Boston Scientific, C. R. Bard, Hologic, Cook Medical, INRAD, Devicor Medical Products, PLANMED OY

• What was the value of the Biopsy Device Market in 2025?

  In 2025, the Biopsy Device Market value stood at USD 2.12 Billion.

Related Reports

Spinal Traction Market Healthcare CRM Market Cryotherapy Market Roxithromycin Tablets Market Creatine Market Blood and Fluid Warmer Market